Rejuvenate brain neurons through cellular reprogramming (Basic Research)

UB RESEARCHERS REJUVENATE BRAIN NEURONS THROUGH CELLULAR REPROGRAMMING: MORE NEURONS AND MORE BRAIN PLASTICITY

Read more

Workshop at the Research Morning (Advanced Therapies)

DYNAMIC WORKSHOP ON CLEAN ROOMS AT THE RESEARCH MORNING DURING THE EUROPEAN RESEARCH NIGHT 2024.

Read more

Farmaforum 2024 (Advanced Therapies)

GREAT SUCCESS AT THE PHARMAFORUM 2024 – BIOTECHFORUM

Read more

4D-Bioskin project (Advanced Therapies)

THE UNIVERSITY OF BARCELONA PARTICIPATES IN A CONSORTIUM TO VALIDATE AND SCALE-UP THE HUMAN SKIN PRODUCTION GENERATED BY A 3D BIOPRINTER

Read more

In memory of Dr Ernest Arenas Cases (1962 – 2024)

Read more

Creatio hosts high school students (Basic Research)

CREATIO HOSTS HIGH SCHOOL STUDENTS TO ASSIST THEM WITH THEIR RESEARCH PROJECTS FOR BACCALAUREATE

Read more

1 Year Preclinical Studies Area

CELEBRATION OF THE 1ST ANNIVERSARY OF THE PRECLINICAL STUDIES AREA – AVANTDRUG – CREATIO/UNIVERSITAT DE BARCELONA

Read more

Discover Creatio

¡DESCUBRE QUÉ VALOR APORTA CREATIO A LA SOCIEDAD!

Read more

Dr. Jordi Abante – Junior Leader “la Caixa” Foundation (Basic Research)

DR. JORDI ABANTE, POSTDOCTORAL RESEARCHER AT CREATIO, OBTAINS A GRANT FROM THE JUNIOR LEADER FELLOWSHIPS - INCOMING PROGRAM OF "LA CAIXA" FOUNDATION

Read more

Ten Spanish universities and research centers participate in the international UniStem Day on stem cells aimed at high school and ESO students (basic research)

Read more

The role of huntingtin (Basic Research)

THE SOLUBLE MUTANT HUNTINGTIN PROTEIN IS ONE OF THE RESPONSIBLE FOR THE SPREADING AND DEVELOPMENT OF HUNTINGTON'S DISEASE IN THE EARLY STAGES

Read more

UTOX acquisition (Preclinical Studies)

THE UNIVERSITY OF BARCELONA PROMOTES INNOVATION AND TRANSFER AND ACQUIRES THE EXPERIMENTAL TOXICOLOGY PLATFORM UTOX OF THE BARCELONA SCIENCE PARK

Read more

ASCTN-INT collaboration paper IBEC-Creatio (Basic Research)

AN OPTIMIZED HYALURONIC ACID- BASED BIOINK COMPATIBLE WITH NEURAL NETWORK FORMATION IS DEVELOPED BY ASCTN-ITN PROJECT

Read more

Position paper about Hospital Exemption -TERAV (Advanced Therapies)

THE SPANISH ADVANCED THERAPY NETWORK HAS RELEASED POSITION PAPER ABOUT THE ROLE OF HOSPITAL EXEMPTION IN EUROPE

Read more

UniStem 2023: An international day to approach science to students (Basic Research)

UNISTEM DAY 2023, HOSTED AT THE UNIVERSITY OF BARCELONA, APPROACHED STEM CELLS AND REGENERATIVE MEDICINE RESEARCH TO MORE THAN 100 HIGH SCHOOL STUDENTS

Read more

Qrem and Creatio will develop a protocol to isolate monocytes – MONOCOL project, INNOTEC grant – ACCIÓ (Advanced Therapies)

QREM REGENERATIVE TECHNOLOGY TOGETHER WITH CREATIO UB WILL DEVELOP AN INNOVATIVE PROTOCOL TO ISOLATE IMMUNE SYSTEM CELLS

Read more

Creatio participates in the report on alternative methods by the JRC (Preclinical Studies)

DR. JOSEP M. CANALS PARTICIPATES IN THE JOINT RESEARCH COUNCIL (JRC) REPORT ON ALTERNATIVE METHODS TO TEST IMMUNOGENECITY FOR THE EUROPEAN COMMISSION (EC)

Read more

EIC Pathfinder: 4-DBR (Basic Research)

4-DEEP BRAIN RECONSTRUCTION (4-DBR), AN INNOVATIVE EUROPEAN PROJECT FOR BRAIN REGENERATION TO TREAT NEURODEGENERATIVE DISORDERS, WAS LAUNCHED IN SEPTEMBER 2022

Read more

Renewal of ISO 9001:2015 (Advanced Therapies)

CREATIO HAS SUCCESSFULLY PASSED THE AUDIT AND RENEWS THE ISO 9001:2015 CERTIFICATION FOR 3 MORE YEARS

Read more

Poietis partnership – Bioprinting (Advanced Therapies)

THE UNIVERSITY OF BARCELONA AND POIETIS ANNOUNCE THEIR PARTNERSHIP TO SET-UP A GMP-COMPLIANT BIOPRINTING FACILITY IN THE PRODUCTION AND VALIDATION CENTER FOR ADVANCED THERAPIES OF THE UNIVERSITY (CREATIO)

Read more

Conference: Dr. Jordi Abante (Basic Research)

DR. JORDI ABANTE LLENAS, POSTDOCTORAL RESEARCH FELLOW AT STANFORD UNIVERSITY (UNITED STATES), WILL GIVE A CONFERENCE ON SEPTEMBER 23rd AT 3:00 P.M. IN THE SALA DOLORS ALEU I RIERA (ROOM 14) OF THE CAMPUS CLINIC (UNIVERSITY OF BARCELONA).

Read more

Paper Cells (Basic Research)

CREATIO’S PAPER DESCRIBING A SIGNIFICANT REDUCTION OF GENOMIC INSTABILITY IN HUMAN STEM CELL LINES UNDER QUALITY MANAGEMENT SYSTEM (QMS) CONDITIONS PUBLISHED AT CELLS

Read more

White Paper (Preclinical Studies)

CREATIO PARTICIPATES IN THE GUIDELINES TO BRING RESEARCH CLOSER TO THE CLINIC FOR HUNTINGTON PATIENTS

Read more

Transmembrane Glycoprotein Alteration (Basic Research)

ALTERATION OF THE CD200-CD200R1 IN HUNTINGTON’S DISEASE IS DESCRIBED FOR THE FIRST TIME

Read more

4D Bioprinter (Advanced Therapies)

CREATIO RECEIVES FUNDING TO ACQUIRE A 4D BIOPRINTER

Read more

Neuronal Reprogramming – Project Foundation La Caixa (Basic Research)

NEURONAL REPROGRAMMING TO SLOW HUNTINGTON'S DISEASE

Read more

SC4HD International Consortium (Advanced Therapies)

A NEW INTERNATIONAL CONSORTIUM TO PROMOTE STEM CELL-BASED THERAPY FOR HUNTINGTON'S DISEASE

Read more

CAR-T ARI-0001 (Advanced Therapies)

CREATIO PARTICIPA EN LA PRODUCCIÓN DE LA TERAPIA AVANZADA CAR-T ARI-0001

Read more

Guideline Cell Produciton (Preclinical Studies)

CREATIO PUBLISHES A GUIDELINE FOR CLINICAL-GRADE HEK293T CELL BANKING FOR LENTIVIRAL PARTICLE PRODUCTION

Read more

FET Open: Neu-Chip (Basic Research)

CREATIO WILL PARTICIPATE IN A NEW EUROPEAN PROJECT, FET-OPEN, LED AT THE UB BY RESEARCHERS JORDI SORIANO AND DANIEL TORNERO

Read more

DataScience Modeling (Basic Research)

CREATIO AND DATASCIENCE COLLABORATE TO DEVELOP AN IN SILICO MODEL FOR DRUG SCREENING IN NEURODEGENERATIVE DISEASES

Read more

Review: Immune Response in Patients (Advanced Therapies)

CREATIO PUBLISHES THE FIRST SCIENTIFIC REVIEW ON THE IMPACT OF THE IMMUNE RESPONSE IN PARKINSON'S AND HUNTINGTON’S PATIENTS TREATED WITH CELL THERAPY, EVALUATING CLINICAL TRIALS CONDUCTED IN THE PAST FOUR DECADES

Read more

Neuroimmunology elucidate Huntington (Basic Research)

CREATIO CONTINUES TO ADVANCE IN THE FIELD OF NEUROIMMUNOLOGY TO ELUCIDATE THE PATHOPHYSIOLOGY OF HUNTINGTON’S DISEASE

Read more

Characterization Molecular Axis – Schizophrenia (Basic Research)

CREATIO EXPANDS RESEARCH INITIATIVES TO SCHIZOPHRENIA AND CONTRIBUTES TO THE CHARACTERIZATION OF A NEW MOLECULAR AXIS RELEVANT FOR THE PATHOPHYSIOLOGY OF THE DISEASE

Read more

Caracterización Eje Molecular – Esquizofrenia (Investigación Básica)

CREATIO EXPANDE SUS HORIZONTES DE INVESTIGACIÓN HACIA OTRAS ENFERMEDADES NEURODEGENERATIVAS; LA ESQUIZOFRENIA Y CONTRIBUYE A LA CARACTERIZACIÓN DE UN NUEVO EJE MOLECULAR RELEVANTE PARA LA FISIOPATOLOGÍA DE LA ENFERMEDAD

Read more

GIVIMP Protocol to Differentiate Cells (Preclinical Studies)

THE FIRST CREATIO’S GIVIMP-COMPATIBLE PROTOCOL TO DIFFERENTIATE PLURIPOTENT STEM CELLS INTO FUNCTIONAL NEURONS

Read more

Avantdrug New Website (Preclinical Studies)

LAUNCH OF THE NEW AVANTDRUG WEBSITE

Read more

CAR-T Production Clinical Trial (Advanced Therapies)

CREATIO CONTRIBUTES TO THE SUCCESSFUL PRODUCTION OF CAR-T CELLS USED IN CLINICAL TRIAL AGAINST BLOOD CANCER

Read more

Avantdrug: Nerotoxicology Platform (Preclinical Studies)

NEUROTOXICOLOGY AND DRUG SCREENING PLATFORM - AVANTDRUG

Read more

ASCTN-Training: Young Researcher Program (Basic Research)

A PROGRAM GIVES 3.8 MILLION EUROS TO TRAIN YOUNG RESEARCHERS IN CELLULAR THERAPIES APPLIED TO NEURONAL DISEASES

Read more

Interview Dr. Canals (Advanced Therapies)

INTERVIEW WITH JOSEP M CANALS FOR ADVANCE(CAT)

Read more

CHDI Foundation Funding (Basic Research)

THE WORLD'S LARGEST FOUNDATION IN THE SEARCH FOR A CURE FOR NEURODEGENERATIVE HUNTINGTON'S DISEASE, CHDI, HAS SHOWN CONTINUED TRUST IN CREATIO FOR THE PAST FEW YEARS.

Read more

Neuroscience 2017 (Basic Research)

NEUROSCIENCE 2017 CONGRESS

Read more

BioJapan 2017 (Basic Research)

RESULTS BIOJAPAN 2017

Read more

Pre-BioJapan 2017 (Basic Research)

BIOJAPAN 2017 - ASIA'S PREMIER PARTNERING EVENT FOR THE GLOBAL BIOTECHNOLOGY INDUSTRY

Read more

Creation ADVANCE(CAT) (Advanced Therapies)

ADVANCE(CAT) CONSORTIUM IS LAUNCH TO PROMOTE ADVANCED THERAPIES IN CATALONIA

Read more

Paper Nature Neuroscience (Basic Research)

AN INTERNATIONAL STUDY WITH THE PARTICIPATION OF THE UB SHOWS THAT HUNTINGTON'S DISEASE ALTERES NEURONS SINCE ITS DEVELOPMENT

Read more